VPTDFVentriPoint Diagnostics Ltd.

About VentriPoint Diagnostics Ltd. (VPTDF)

VentriPoint Diagnostics Ltd. (VPTDF) is a Medical Devices company headquartered in Toronto, ON, Canada whose shares trade over-the-counter on the Pink tier.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

Products and services

Cardiac ultrasound analysis of all 4 chambers of the heart from 2D and 3D ultrasound scans as well as MRI datasets. Uniquely able to provide ejection fraction and volumes for right ventricle and right atrium from 2D ultrasound exams with equivalent accuracy and precision as MRI in 2 minutes of analysis. Simple to learn and excellent interobserver reproducibility. Approved for clinical use for all patients in the United States, Canada, Europe and China.

VPTDF key facts

Ticker symbol

VPTDF

Market tier

Pink

Sector

Healthcare

Industry

Medical Devices

Headquarters

Toronto, ON, Canada

Country of incorporation

CA

Year of incorporation

2007

Employees

10

Estimated market cap

$17.76M (as of Apr 9, 2025)

Shares outstanding

163,057,280

Reporting standard

International Reporting: TSX Venture Exchange

Audit status

Audited

Fiscal year end

12/31

Latest filing

Quarterly Report (Sep 30, 2024)

VentriPoint Diagnostics Ltd. leadership

• Hugh MacNaught — Interim CEO
• Jimmy Jeon — CFO
• Victor Hugo — Other

Explore more: Medical Devices stocks · Healthcare sector · Pink stocks · OTC stocks starting with V